|Writing Group Member||Employment||Consultant||Speaker||Ownership/Partnership/Principal||Research||Institutional, Organizational, or Other Financial Benefit||Expert Witness|
|Frederick G. Kushner, Co-Chair||Tulane University School of Medicine—Clinical Professor of Medicine; Heart Clinic of Louisiana—Medical Director||None||Abbott; Bristol-Myers Squibb||None||Daiichi-Sankyo||None||None|
|Mary Hand, Co-Chair||Agency for Healthcare Research and Quality—Health Science Administrator||None||None||None||None||None||None|
|Elliott M. Antman||Brigham and Women's Hospital||Momenta Pharmaceuticals; Sanofi-aventis||Eli Lilly; Sanofi-aventis||None||Accumetrics; Amgen, Inc; AstraZeneca Pharmaceuticals; Bayer Healthcare; Beckman Coulter; Biosite; Bristol-Myers Squibb Pharmaceutical Research Institute; CV Therapeutics; Daiichi-Sankyo⁎; Eli Lilly⁎; GlaxoSmithKline; Inotek Pharmaceuticals Corp; Integrated Therapeutics Corp; Merck; Millennium Pharmaceuticals; National Institutes of Health; Novartis Pharmaceuticals; Nuvelo; Ortho Clinical Diagnostics; Pfizer; Roche Diagnostics Corp; Roche Diagnostics GmbH; Sanofi-aventis⁎; Sanofi-Synthelabo Recherche; Schering-Plough Research Institute||None||None|
|Eric R. Bates||University of Michigan—Professor of Medicine||Bristol-Myers Squibb; Daiichi-Sankyo; Eli Lilly; Novartis; Takeda||Boehringer Ingelheim; Daiichi-Sankyo; Eli Lilly; Sanofi-aventis||None||Eli Lilly⁎||None||None|
|Donald E. Casey, Jr||Atlantic Health—Chief Medical Officer and Vice President of Quality||None||None||None||None||None||None|
|Lee A. Green||University of Michigan —Associate Professor, Dept. of Family Medicine||None||None||None||None||None||None|
|Judith S. Hochman||New York University School of Medicine—Clinical Chief of Cardiology||GlaxoSmithKline||None||None||Bayer HealthCare AG; Eli Lilly; Johnson & Johnson Pharmaceutical Research & Development; Millennium Pharmaceuticals; Schering-Plough Research Institute||None||None|
|Harlan M. Krumholz||Yale University School of Medicine—Harold H. Hines, Jr. Professor of Medicine and Epidemiology and Public Health||United Healthcare⁎||None||None||Centers for Medicare and Medicaid Services⁎||None||None|
|Joseph P. Ornato||Virginia Commonwealth University Health System—Professor and Chair, Dept. of Emergency Medicine||None||Bristol-Myers Squibb/Sanofi-aventis||None||None||None||None|
|David L. Pearle||Georgetown University Hospital—Professor of Medicine||None||None;||None||None||None||None|
|Michael A. Sloan||University of South Florida—Professor and Director, USF Stroke Program||None||Boehringer Ingelheim; Genentech; National Association for Continuing Education||None||None||None||Anoxic Encephalopathy, 2006; Acute Stroke Intervention, 2006–7; Carotid Endarterectomy, 2006|
|Sidney C. Smith, Jr||Center for Cardiovascular Science and Medicine—Professor of Medicine; Director||None||None||None||None||None||None|
This table represents the relationships of committee members with industry that were reported at the Task Force on Practice Guidelines meeting and updated in conjunction with all meetings. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity or ownership of $10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted.
↵⁎ Significant (greater than $10 000) relationship.